The California-based company, founded in 2014, is rapidly building a strong pipeline of therapeutics across various therapeutic areas, including its most advanced asset, DYV-700, which is currently in phase 2 for the treatment of acute gout. Dyve's proprietary science enables injection-like delivery of molecules across the skin, providing a transient way to bring molecules through the skin and allowing rapid penetration into targeted tissue. This technology facilitates therapy for treating adipolysis, hyperpigmentation, and lateral canthal lines.